AMDL

AMDL closes Jade Pharmaceutical acquisition

Published in Cancer Law Weekly, October 28th, 2006

AMDL, Inc., (ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, announced that the acquisition of Jade Pharmaceutical, Inc., (JPI) and its two wholly owned China based subsidiaries for an aggregate of 2,743,000 post-reverse split (13,715,000 pre-reverse split) shares of AMDL common stock.

The JPI acquisition was closed on September 28, 2006, immediately after the filing of a Certificate of Amendment to AMDL's Certificate of Incorporation increasing AMDL's authorized Common Stock and reverse splitting the outstanding shares of Common Stock. The stockholders approved these proposals at the meeting held on September 8, 2006....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Law Weekly

Source: Cancer Law Weekly (2006-10-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry